title: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts.
abstract: OBJECTIVE
  Evaluation of skin layer-specific prednicarbate (PC) biotransformation, possibly explaining the improved benefit/risk ratio of this topical corticosteroid in atopic dermatitis (1,2).
  
  
  METHODS
  Metabolism of PC in keratinocyte and fibroblast monolayers derived from human juvenile foreskin was evaluated. Drug concentration was determined by HPLC/UV-absorption. Accompanying cell viability tests (MTT-tests) were performed to exclude toxic drug effects.
  
  
  RESULTS
  Keratinocytes hydrolyzed the double ester PC (2.5 x 10(-5) M) at position 21 to the monoester prednisolone 17-ethylcarbonate (P17EC) which nonenzymatically transformed to prednisolone 21-ethylcarbonate (P21EC). This metabolite was enzymatically cleaved to prednisolone (PD), the main biotransformation product at 24 hours. Fibroblasts, however, showed a distinctively lower enzyme activity. Both, PC and P17EC (or rather P21EC) were hydrolyzed to a minor extent only. The biotransformation pathway, however, was the same. When P17EC was added separately, it transformed to P21EC and again was cleaved by keratinocytes to a much higher extent. Despite of the rather high glucocorticoid concentration MTT-tests proved a non-disturbed cell viability and proliferation rate.
  
  
  CONCLUSIONS
  Extrapolating our results to the in-vivo situation, topically applied PC may be metabolized by epidermal cells during skin penetration. A complex mixture of compounds reaches the dermis, whose fibroblasts are barely able to metabolize the steroids. Since skin atrophy is less pronounced with PC as compared to conventional halogenated glucocorticoids, less potent PC metabolites appear to be the dominant species in the dermis.
authors.affiliation: Abteilung für Pharmakologie und Toxikologie, Freie Universität Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Gysler
authors.forename: K
authors.initials: K
authors.lastname: Lange
authors.forename: H C
authors.initials: HC
authors.lastname: Korting
authors.forename: M
authors.initials: M
authors.lastname: Schäfer-Korting
mesh_terms: D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics*; D001711:Biotransformation; D002470:Cell Survival; D002851:Chromatography, High Pressure Liquid; D005347:Fibroblasts / Q000378:metabolism; D005938:Glucocorticoids; D006801:Humans; D015603:Keratinocytes / Q000378:metabolism; D008297:Male; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D012867:Skin / Q000166:cytology / Q000378:metabolism*; D013778:Tetrazolium Salts; D013844:Thiazoles
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D013778:Tetrazolium Salts; D013844:Thiazoles; C085709:prednisolone 17-ethylcarbonate; D011239:Prednisolone; C022616:thiazolyl blue; C035287:prednicarbate